We previously reported the nano-surface and molecular-orientation limited (nSMOL) proteolysis, which is a novel method for selective quantitation of monoclonal antibody Fab. The nSMOL strategy is a Fab-selective limited proteolysis which utilizes the size difference between the protease nanoparticle (200 nm) and the antibody resin pore (100 nm). Here, we applied this method to a fully validated LCMS analysis of Nivolumab in human plasma. The immunoglobulin fraction was collected using Protein A resin, which was then followed by nSMOL reaction using the FG nanoparticle surface-immobilized trypsin under a nondenaturing physiological condition at 50
Introduction
Programmed cell death-1 (PD-1, CD279), originally identified by Honjo et al. [1] , is a type-1 transmembrane immunoreceptor related to the CD28/cytotoxic T-lymphocyte-associated antigen 4 (CTCL-4) family, which negatively regulates the immune response pathways in T-cells [2, 3] . This immunological significance led to its numerous clinical benefit such as for autoimmunity, infectious elements, and cancer immunotherapies [4] . It is conceivable that there are three stages of immune editing systems in cancer cells: elimination, equilibrium, and escape [5] . Therefore, blockade of the inhibitory antitumor T-cell response called the immune checkpoint has been a major therapeutic target for many cancer eradication. A highly specific monoclonal antibody Nivolumab is a fully human IgG4 monoclonal antibody targeting PD-1 and it is approved by the Food and Drug Administration in 2011 as a new drug for melanoma. T-cells assume definitive roles in immune cell-mediated cancer immunity via a complex cell-to-cell signaling. Long-term cancer controls is one clinical outcome achieved by immune checkpoint inhibitors, by regulating the accelerated and/or suppressive immune balance. This mechanism of immunotherapy has also received great attention for the treatment of non-small-cell lung [6] [7] [8] , renal cell carcinomas [9] , ovary [10] , bladder [11] , and prostate cancers [12] , glioblastoma [13] , lymphoma [14] , and many other tumour types. However, Nivolumab and other immune checkpoint agents are known to cause several immune-related adverse events such as dermatological, gastrointestinal, endocrine, hepatic, neurological, and other effects on other organs [15] [16] [17] . It is challenging to address the precision immunotherapy for cancers due to the complexity of diverse immune interactions. Thus, identification of predictive and pharmacodynamic biomarkers or marker panels for drug efficacy will be crucial for a more effective cancer immunotherapy [18] . We expect that an overall clinical pharmacokinetics (PK) can be used as a good indicator for drug efficacy and for predicting the effects on the immune response. However, how PK findings of these inhibitors may translate to their clinical outcomes is yet to be determined.
In the field of clinical PK, ligand binding assay (LBA) is currently the first choice for quantitating therapeutic antibodies. However, in some cases, LBA is not a reasonable method for antibody quantitation. For example, neutralizing antibodies called antidrug antibodies (ADA) inhibit specific binding of antigen to drugs, contributing to unexpected errors [19] . Furthermore, speciesspecificity can cause limitation in translating findings obtained using preclinical animal models into clinical studies in human. Currently, cancer care utilizes combined chemotherapy strategies using next generation molecular target compounds, antibodies, and antibody-drug conjugates (ADC). Therefore, a more selective, sensitive, and universal technology independent of a variety of antibody agents will be desirable. Nivolumab is a fully human antibody; thus, an accurate quantitation of signature peptides with a complete structural determination is especially important since the specific regions of antibody drugs are shorter than those of the endogenous immunoglobulins with high sequence homology. Recently, liquid chromatography-triple quadrupole mass spectrometry (LC-TQMS) was applied to quantitate therapeutic antibodies in biological fluid.
LCMS is a more selective and sensitive method to quantitate the antibody specific regions. Further, it allows for multiplex assay development in a more shorter period of time, without the hassle of specific collection and detection antibodies in LBA method [20, 21] .
However, to develop LCMS at the level of regulated bioanalysis, necessary improvements will need to be done for greater precision and accuracy, dynamic range, and universal applicability for antibody drugs. Plasma is a complex biological mixture, and tryptic peptides from this matrix are large excess analytes for LCMS. Excess peptide mixtures and protease contamination can cause ionization suppression, carryover, noise elevation, lower dynamic range and retention time reproducibility, and column sustainability. To overcome these issues, we recently reported a novel method for selective proteolysis of the Fab by limiting protease access to the substrate, which we termed the nano-surface and molecularorientation limited (nSMOL) proteolysis [22] . The nSMOL chemistry was designed as a solid-solid proteolysis as follows: (1) protease reaction on a uniform nanoparticle surface to raise the accessibility to the substrate; (2) Fc immobilization onto the resin via Protein A, such that the Fab is oriented outward to the reaction solution; and (3) Fab-selective proteolysis by making use of the difference in the protease nanoparticle diameter (200 nm) and the antibody resin pore (100 nm). The nSMOL has allowed us to minimize sample complexity while maintaining the specificity of peptides in the complementarity-determining region (CDR). Furthermore, this method has allowed for effective proteolysis on Fab by using a nondenaturing physiological condition, absence of extra trypsin contamination in the analyte, absence of further peptide purification such as solid-phase extraction, and independent of a variety of antibodies. In this study, we demonstrate a validated LCMS analysis of Nivolumab in plasma using the nSMOL [23, 24] .
Materials and methods

Reagents
Glycidyl methacrylate (GMA)-coated nano-ferrite particle FG beads with surface activation by NHS group was purchased from Tamagawa Seiki (Nagano, Japan). Toyopearl AF-rProtein A HC-650F resin was from Tosoh (Tokyo, Japan). Nivolumab (OPDIVO) was purchased from Ono Pharmaceutical (Osaka, Japan). Individual male and female control human plasma (EDTA-2K treated) was from Kohjin Bio (Saitama, Japan). Trypsin gold was from Promega (Fitchburg, WI). n-octyl-␤-d-thioglucopyranoside (OTG) was from Dojindo Laboratories (Kumamoto, Japan). P14R internal standard synthetic peptide was from Sigma Aldrich (St. Louis, MO). Ultrafree-MC GV centrifugal filter was from Merck Millipore (Billerica, MA). Other reagents, buffers, and solvents were from Sigma-Aldrich and Wako Pure Chemical Industries (Osaka, Japan).
Peptide structure identification of Nivolumab peptides
Two microlitre of Nivolumab (20 g) was digested using 1 g of trypsin in 150 l of 25 mM tris-HCl buffer (pH 8.0) containing 1 mM tris(2-carboxyethyl)phosphine-HCl salt (TCEP) at 37 • C for 16 h. Trypsin digestion was quenched by adding 10% formic acid solution at a final concentration of 0.5%. For nSMOL reactions, 20 g of Nivolumab was collected with 10 l of PBS-substituted AF-rProtein A resin (50% slurry) with gentle vortexing at 25 • C for 10 min. Protein A resin was recovered on an Ultrafree filter, washed twice using 300 l of PBS by centrifugation (10,000g for 1 min), and substituted with 150 l of 25 mM tris-HCl (pH 8.0). nSMOL reaction was carried out using 1 g of trypsin on FG-beads with gentle vortexing at 37 • C for 16 h in saturated vapour atmosphere. After proteolysis, reaction was stopped by adding 10% formic acid at a final concentration of 0.5%. The peptide solution was collected by centrifugation (10,000g for 1 min) to remove Protein A resin and trypsin FG-beads. Structure of tryptic peptides from Nivolumab were analysed by high-resolution liquid chromatography-linear ion trap time-of-flight MS (Nexera X2 ultra high performance liquid chromatograph and LCMS-IT-TOF, Shimadzu, Kyoto, Japan), and fragment ions were assigned using an in-house Mascot server and Distiller with Nivolumab amino acid sequence information (Matrix Science, London, UK). The LCMS conditions were as follows: solvent A, 0.1% aqueous formic acid; solvent B, acetonitrile with 0.1% formic acid; column, L-column2 ODS, 2.1 × 150 mm, 2 m, 10 nm pore (Chemicals Evaluation and Research Institute, Tokyo, Japan); column temperature, 50 • C; flow rate, 0.2 ml/min; gradient program, 0-5 min: %B = 3, 5-35 min: %B = 3-30 gradient, 35-46 min: %B = 95, 46-55 min: %B = 3. MS and MS/MS spectra were obtained using desolvation line and heat block at 200 • C, respectively. Nebulizer nitrogen gas flows were set to 1.5 l/min. Drying gas pressure was 100 kPa. Ion accumulation time was 30 ms for MS, and 70 ms for MS/MS analysis. MS/MS analysis was performed using the automated data dependent mode. Ar pulse time into the ion trap cell was 125 s. The electrode of collision-induced dissociation (CID) cell was set at −1.5 V.
Prediction of Nivolumab signature peptides
Amino acid sequences of antibody drugs were obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG) DRUG. Multiple alignment was performed using the amino acid sequence of Nivolumab (KEGG DRUG entry D10316), Tremelimumab (D06657), Ipilimumab (D04603), and Ramucirumab (D09371) by ClustalW algorithm on GENETYX software (GENETYX, Tokyo, Japan). In this analysis, theoretical tryptic peptides containing the CDR sequence, amino acid substitution, positions of conserved cysteine residues, and insertion or deletion of amino acids were aligned.
Condition setting of multiple reaction monitoring for Nivolumab peptides
The peptide quantitation was analysed using an LC-electrospray ionization-MS (LC-ESI-MS) with triple quadrupole (Nexera X2 and LCMS-8050, Shimadzu). The LCMS conditions were as follows: solvent A, 0.1% aqueous formic acid; solvent B, acetonitrile with 0.1% formic acid; column, Shim-pack GISS C18, 2.1 × 50 mm, 1.9 m, 20 nm pore (Shimadzu); column temperature, 50 • C; flow rate, 0.4 ml/min; gradient program, 0-1.5 min: %B = 1, 1.5-4.5 min: %B = 1-40 gradient, 4.5-5.5 min: %B = 95 with flow rate 1 ml/min, 5.5-6 min: %B = 1 with flow rate 1 mi/min, and 6-6.5 min: %B = 1. MS spectra were obtained with ESI probe temperature, desolvation line, and heat block at 300 • C, 250 • C and 400 • C, respectively. Nebulizer, heating, and drying nitrogen gas flows were set to 3, 10, and 10 l/min, respectively. The dwell time was set to 10 ms for each transition. MRM monitor ions of peptide fragments were imported from the measured values of structure-assigned fragments by highresolution LCMS analysis. CID Ar partial pressure in the Q2 cell was set to 270 kPa. The electrode voltage of Q1 pre bias, collision cell Q2, Q3 pre bias, and parent and fragment ion m/z were optimized using the LabSolution software (Shimadzu). For MRM transition, one fragment ion of b-or y-series was selected for quantitation, and two ions for structural confirmation according to the optimized MRM ion yield.
Validation sample preparation of Nivolumab analysis
In the current study, we performed a bioanalytical validation of Nivolumab in plasma using the nSMOL method as described in our previous report with a minor improvement [22] . Briefly, all validation sample sets were prepared and stored at −20 • C or −80 • C for 24 h or longer before each validation assay. A 20 l aliquot of Nivolumab-spiked human plasma was diluted 10-fold in PBS (pH 7.4) containing 0.1% OTG. The Ig fraction was collected with 50 l of PBS-substituted AF-rProtein A resin (50% slurry) with gentle vortexing at 25 • C for 15 min. Protein A resin was collected onto Ultrafree filter and washed twice with 300 l PBS containing OTG, centrifuged (10,000g for 1 min), and substituted with 150 l of 25 mM tris-HCl (pH8.0) containing 10 pmol/ml P14R and 2 mM TCEP. nSMOL proteolysis was carried out using 25 g trypsin on FG-beads with gentle vortexing at 50 • C for 7 h in saturated vapour atmosphere. After nSMOL, reaction was stopped by adding 10% formic acid at a final concentration of 0.5%. The peptide solution was collected by centrifugation (10,000g for 1 min) to remove Protein A resin and trypsin FG-beads. These analytes were transferred into low protein binding polypropylene vials for LCMS analysis. The concentration of Nivolumab in plasma samples was set from 0.977 to 250 g/ml with two-fold serial dilution for nine calibration samples. The concentrations of lower limit of quantification (LLOQ), low quality control (LQC), middle quality control (MQC), and high quality control (HQC) were set to 0.977, 2.93, 23.4, and 200 g/ml, respectively.
Results
Structural confirmation of Nivolumab peptides by LCMS-IT-TOF MS and ClustalW analysis
The identification of tryptic Nivolumab peptides was performed using a high-resolution LC-TOF MS/MS analysis and Mascot server. Five peptides from the heavy chain and three from the light chain on Fv were assigned with significant Mascot score, and summarized in Table 1 . Peptide regions were shown as ClustalW alignment results of four fully human therapeutic antibodies (Fig. 1) . To select signature peptides, we have established a criteria in our previous report: peptides with 8-15 amino acid sequences, with no missed cleavage, no cysteine residue, and exclusion of the vicinity of the conserved disulphide bonding on the framework structure. Optimized MRM transitions of each peptide are shown in Table 2 , with one fragment for quantitation and an additional two fragments for structural confirmation.
Nivolumab peptides interference from human plasma
To determine interference of Nivolumab peptides from human plasma, each candidate peptide was analysed using 4.69-37.5 g/ml of sample with two-fold serial dilution in plasma. Not all CDR peptides can be used as the specific peptide for nSMOL bioanalysis, due to the exceedingly diverse set of CDR sequences in endogenous immunoglobulins. The peptide ASGITFSNSGMH-WVR (MW 1649.8) was selected as the signature Nivolumab peptide as we showed no interference from human plasma and a good correlation with Nivolumab concentrations (Fig. 2a) . In contrast, for example of LLIYDASNR peptide, showed no correlation to Nivolumab concentrations demonstrating a competition from endogenous immunoglobulins (Fig. 2b) .
Bioanalytical validation
The bioanalytical method was validated according to the Guideline on Bioanalytical Method Validation in Pharmaceutical Development from Notification 0711-1 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, the Ministry of Health, Labour and Welfare, dated July 11, 2013 for low 
Selectivity
For the individual human plasma controls from three males and three females, no interference peak in the MRM chromatograms were detected for the ASGITFSNSGMHWVR signature Nivolumab peptide. Minimal response was observed from interfering substance at the retention time of 3.75 min corresponding to the signature Nivolumab peptide. Representative MRM chromatograms of the signature Nivolumab peptide are shown in Fig. 3. 
Matrix effect
Individual plasma samples from three males and three females were analysed for matrix effect test at the LQC and HQC concentrations. The response ratio of Nivolumab peptide in plasma prior to each sample preparation step was compared to that of PBS. Matrix factors of P14R-corrected value at LQC and HQC were 9.72% and 7.27%, respectively, which were within the accepted criteria of precision (CV) of <15% (Table S1 in Supporting information).
Carryover
The carryover test was performed by analysing three replicates for Nivolumab peptide and one run for P14R immediately after the high concentration (250 g/ml) analysis. The carryover was calculated as percent response in the blank plasma relative to the preceding sample. In nSMOL analysis, carryover was observed at 0.151-0.172% for the Nivolumab peptide and no carryover was observed for P14R, confirming minimal levels of carryover influencing our analysis (Table S2 in Supporting information).
Linearity and calibration standard
The linearity of nSMOL protocols was evaluated by analysing nine calibration standards (zero sample, 0.977, 1.95, 3.91, 7.81, 15.6, 31.3, 62.5, 125, and 250 g/ml) using the linear regression model. The calibration plot of weighting was done using the 1/area 2 method. The calibration fit formulas of the triplicate runs were Y = 0.0627X + 0.0211 (r = 0.997), Y = 0.0585X + 0.00507 (r = 0.997), and Y = 0.0750X + 0.0434202 (r = 0.996) (r: correlation coefficient). The accuracy at LLOQ was 91.9-97.0%, and at other concentrations were 91.1-111% (Table S3 in Supporting information). 
Precision and accuracy in inter-and intra-assays
Precision and accuracy were determined by analysis of human plasma validation sample at LLOQ, LQC, MQC, and HQC of Nivolumab concentrations. The intra-day and inter-day precision and accuracy were determined by analysing five sets of QC samples at four concentration levels on three different days. Precision and accuracy data were: run 1, 92.7% and 17.9% at LLOQ, 102-112% and 7.11-9.25% at other concentrations; run 2, 109% and 11.2% at LLOQ, 99.0-103%, 2.51-7.86% at other concentrations; run 3, 87.0% and 7.56% at LLOQ, 98.4-101%, 4.78-6.99% at other concentrations; intra-assay (N = 15), 96.1% and 15.6% at LLOQ, 101-105%, 6.75-8.01% at other concentrations (Table 3 ).
Lower Limit of Quantification (LLOQ)
The LLOQ was defined as the lowest concentration of the calibration curve with acceptable precision and accuracy, which were determined to be 0.977 g/ml (Table S4 ). According to the package insert of Nivolumab from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, the Cmax concentrations of Nivolumab Phase I trial (CA209001) in a single-dose administration for melanoma cancer patients were 6.7, 16.0, 60.0, and 196.3 g/ml for 0.3, 1, 3, and 10 mg/kg dose, respectively, indicating that the nSMOL quantitation was sufficient to cover Nivolumab clinical concentration spectrum in the plasma. Thus, the nSMOL method was adequate to monitor PK of Nivolumab.
Dilution integrity
The effect of dilution on the analysis of Nivolumab concentration was assessed by preparing spiked validation human plasma at a concentration of 500 g/ml. The 10-and 25-fold dilution of the five validation samples were analysed within the calibration range. The precision and accuracy of the diluted samples were 7.92% and 95.4%, 9.27% and 109%, for 10-and 25-fold dilutions, respectively. These values were within the criteria of decision, suggesting an absence of interference from dilution (Table S4 in Supporting information).
Stability
The stability following five freeze-thaw cycles at −20 • C and −80 • C with at least 12 h of frozen time, short-term stability at room temperature for 4 h prior to sample treatment, long-term stability at −20 • C and −80 • C for 30 days, and processed sample stability at 5 • C for 24 and 48 h were demonstrated at the LQC and HQC concentrations. The accuracy of the initial value for five freeze-thaw cycles at LQC and HQC in −20 • C was 95.6% and 96.1%, respectively, and in −80 • C was 87.5% and 101%, respectively (Table 4 ).
Discussion
We have developed a practical and versatile analytical method to assess Nivolumab plasma concentration in patients. As demonstrated by the present validation study, this method was able to provide a robust determination of Nivolumab in human plasma. All concentration points have reproducibly passed the guideline criteria for low molecular weight drug compounds. Especially mentioned, nSMOL approach has been even acceptable for the normal freezing storage at −20 • C. These advantages will be expected to support for the broad clinical PK study. We believe that this assay is suitable for routine analyses of plasma Nivolumab concentration to study the correlations between its PK profile and drug efficacy and/or adverse events in clinical practice, thereby aiding the development of a precision medicine for patients receiving Nivolumab alone or in combination with other anticancer agents. The essence of cancer immunotherapy is to control the immune cell activity in a complex immune system by immune checkpoint blockade. However, immune checkpoint inhibitors have been linked to side effects. Although various studies have helped elucidate cancer immunity, a detailed mechanism-based immunotherapy which also takes into account the complex tumour microenvironment and diverse tumour tissue types will be necessary.
Expression of PD-1 ligand (PD-L1, PD-L2) in some cancer cells or in immune cells within the tumour microenvironment has been strongly correlated to negative prognosis. The response rates of 44% for PD-L1-positive tumours and 17% for PD-L1-negative tumours were reported in a phase I trial of Nivolumab [4, 25] . However, these response rates did not translate to overall survivals [26] . To decide the optimal efficacy of immune checkpoint inhibitors, medical oncologists will require a conventional tool to predict clinical efficacy and to manage adverse events. Recently, PK-guided treatment such that as by therapeutic drug monitoring for cancer chemotherapy has gained an increasing level of interest. This is due to the current lack of available tools besides LBA to determine plasma concentration of antibody drugs in a clinical setting. Mass spectrometry has the potential to support the PK study of antibody agents because of its superior selectivity for drug structure-indicated quantitation. nSMOL is an novel method for the quantitation of antibody-specific CDRs from blood and tissue homogenate, independent of a variety of antibody agents [22] . nSMOL analysis will allow for accurate quantitation of antibody agents in the blood with the additional benefits of specific structure confirmation and multiplex assay development. Based on our bioanalytical validation study, we have shown that nSMOL can be sufficiently used to determine Nivolumab clinical PK.
In conclusion, we have first demonstrated a fully validated analysis of Nivolumab in human plasma using nSMOL coupled with LC-MS/MS. This analytical approach can be applied to other monoclonal antibodies. Moreover, our study demonstrates that the nSMOL method can be expected in future clinical pharmacokinetic studies for antibody drug development and therapy.
